STOMPing Out Hormone-Sensitive Metastases With Local Therapies in Prostate Cancer
Mené sur 62 patients atteints d'un cancer de la prostate asymptomatique avec trois métastases extracrâniennes au maximum et récidive biochimique après traitement curatif (durée médiane de suivi : 3 ans), cet essai multicentrique de phase II évalue le bénéfice, en termes de survie sans traitement anti-androgénique, d'une intervention chirurgicale ou d'une radiothérapie corporelle stéréotaxique ciblant les métastases
With advances in detection and primary treatment, both with radical prostatectomy and definitive radiotherapy, the 92% of men diagnosed with prostate cancer in the local or regional stage can expect to live for decades with appropriate intervention.1 The long disease-specific and overall survival observed with treated hormone-sensitive prostate cancer, particularly in the localized setting, are a result not only of primary treatment modalities, but also of the ever-evolving armamentarium of treatment approaches for men who recur, either locally or distantly, after definitive treatment. The management of locoregional recurrent prostate cancer comprises local salvage approaches including external-beam radiotherapy (EBRT), brachytherapy, prostatectomy, and cryotherapy, together with restaging to assess for nodal or distant metastases.
Journal of Clinical Oncology , éditorial en libre accès, 2016